Lung cancer is the cancer with the greatest incidence all over the world (11.6% of all cases) and it also represents the main cause of cancer death.1,2 The majority of the patients with lung cancer are diagnosed in metastatic stage which has a 5-year survival rate of 4.7%.3 Among the histological types, non-small cell lung cancer (NSCLC) is the most common, representing around 80% to 85% of all cases in which approximately 40% are adenocarcinoma, 25% to 30% are squamous carcinoma, and 10% to 15% are large cell carcinomas.4–6

In the era of precision medicine, the therapeutic decisions for lung cancer are very dependent on histological and molecular characterization.7 NSCLC is considered a heterogeneous disease with diverse molecular characteristics.8 NSCLC has become an eminent example of precision medicine among solid tumors.9

In personalized medicine, patients are selected for a specific treatment based on the presence of specific biomarkers which indicates a greater chance of the patient to benefit from the treatment.10 Therapeutic options for NSCLCs have increased significantly with the emergence of targeted therapies and immunotherapies.10

The National Comprehensive Cancer Network (NCCN) guideline recommends that patients with aNSCLC should be tested for epidermal growth factor receptor (EGFR); anaplastic lymphoma kinase (ALK); ROS proto-oncogene 1, receptor tyrosine kinase (ROS-1); serine/threonine-protein kinase B-Raf (BRAF); MET proto-oncogene, receptor tyrosine kinase (MET) exon 14 skipping; RET proto-oncogene (RET); neurotrophic receptor tyrosine kinase (NTRK); and programmed death-ligand 1 (PD-L1).11 The NCCN guideline strongly advises the use of broad molecular profiling in order to identify rare driver mutations for which drugs may be available.11 However, approximately 20% to 30% of patients with NSCLC have insufficient tissue material to assess oncogenic driver mutations.12,13 In this situation, the NCCN guideline also recommends plasma testing in NSCLC patients in order to detect EGFR, ALK, ROS-1, BRAF, MET, and RET.11

Liquid biopsy is a less invasive procedure that can access the bloodstream through a needle stick, avoiding the risks of tissue biopsies. Circulating tumor DNA (ctDNA) can be used to provide the same genetic information as a tissue biopsy necessary to interrogate key companion diagnostics.14 Besides, liquid biopsy can also overcome other limitations of tissue biopsies such as detecting tumor heterogeneity and the molecular changes in cancer cells after they are exposed to therapy.14–17

The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) recommends liquid biopsy not as a replacement for tissue biopsy but in cases that there is insufficient tumor tissue specimens or in cases where tissue specimens are not feasible.18 The CAP/IASLC/AMP considers next-generation sequencing panel using ctDNA (ctDNA NGS) a reliable platform in which it can assess single-base variants, indels, copy number changes, and translocations and it can reach acceptable sensitivity and optimal specificity.18

Until now, no meta-analysis has been published to evaluate the diagnostic performance of ctDNA NGS in patients with advanced NSCLC. Thus, we conducted a systematic review and a meta-analysis in order to investigate the diagnostic accuracy of ctDNA NGS in detecting the six oncogenic driver mutations: EGFR, ALK, ROS-1, BRAF, RET, and MET exon 14 in patients with advanced NSCLC.


Study Design

A comprehensive electronic search was performed and included studies that were published until May 2019 in the following databases: MEDLINE/PubMed, The Cochrane Library, Latin American and Caribbean Health Sciences Literature (LILACS), and Centre for Reviews and Dissemination. A gray literature search was also performed in order to detect non-indexed publications.

Search Strategy and Study Selection

Search strategy was defined in order to answer the following question: “Is the ctDNA NGS panel an accurate test to detect oncogenic driver mutations in patients with aNSCLC when compared to tissue genotyping method?” (Table S1).

Specific keywords and terms for each database were considered. The strategies used in each database are shown in Table S2. Article language was limited to English.

Studies were eligible when ctDNA NGS was applied to detect at least one of the following biomarkers in aNSCLC patients: EGFR, ALK, ROS-1, BRAF, RET, and MET exon 14 alterations. Also, studies must use any tissue genotyping method as the gold standard. Exclusion criteria included the absence of sensitivity or specificity data, the analysis of patients with diagnoses other than aNSCLC or healthy subjects. Two reviewers (Ho and Sebastião) evaluated eligibility of studies according to these criteria.

Data Extraction

Two reviewers (Ho and Sebastião) extracted data from all eligible studies. Name of first author, year of publication, histologic type of NSCLC, clinical stage, comparator (“gold standard”), and diagnostic results for EGFR, ALK, ROS-1, BRAF, RET, and MET exon 14 alterations—true positive (TP), false positive (FP), false negative (FN), and true negative (TN)—were collected from eligible studies. EGFR T790M was also considered in our analysis. Genomic alterations in EGFR, ALK, ROS-1, BRAF, RET, and MET exon 14 evaluated by tissue genotyping were considered the “gold standard.”

Quality Assessment

The quality of included studies was assessed using the standardized instrument Quality Assessment of Diagnostic Accuracy Tests (QUADAS-2). QUADAS-2 is designed to assess the quality of primary diagnostic accuracy studies. This tool evaluates the studies based on four key domains: patient selection, index test, reference standard, and flow and timing. Two reviewers (Ho and Sebastião) evaluated the quality of eligible studies.19,20

Statistical Analysis

To assess the test accuracy, data of TP, FP, FN, and TN were tabulated and stratified by study. These diagnostic data were used to calculate the pooled sensitivity, specificity, and diagnostic odds ratio (DOR).

Statistical analysis was performed using the summary Receiver Operating Characteristic (sROC) and the bivariate approach. The sROC is the standard method for meta-analysis of diagnostic accuracy. The bivariate model jointly analyzes the sensitivity and specificity, considering any correlation between these two parameters using a random effect model.21

The heterogeneity between studies was measured by Cochran’s Q test to test the inconsistency index (I2) (p < 0.05 or I2 >50%).22

All statistical analysis was performed with software R, v.4.0.0. The bivariate was fitted by the mada package which is based on the bivariate model of Reitsma et al, bivariate random effects model.21


Characteristics of Eligible Studies

Searches returned 477 citations that were published until May 2019. After screening using the predefined eligibility criteria, 10 studies were included (Figure 1).13,23–31

Figure 1
Figure 1.Study Selection Flowchart

Abbreviations: LILACS, Latin American and Caribbean Health Sciences Literature.

General characteristics of the 10 studies included in the review are reported on Table 1. A total of 2116 results from patients with histologically-confirmed diagnosis of advanced NSCLC with ctDNA NGS were evaluated for the six oncogenic driver mutations. Only data from advanced clinical stages were considered in the study. Two studies selected also reported data from patients with NSCLC in early (I–IIIA) stages, but only data from advanced (IIIB–IV) stages were considered. All studies evaluated the accuracy of NGS ctDNA with tissue genotyping, which may have included polymerase chain reaction (PCR) testing, fluorescence in situ hybridization (FISH) and/or immunohistochemical (IHC), or Sanger sequencing. Exclusion reasons for full-text excluded citations are described in Table S3.

Table 1.Characteristics of Eligible Studies
Study Year Comparator Clinical Stage Driver Mutation
Rachiglio et al24 2016 NGS tissue and confirmed with ddPCR in tissue and plasma Advanced EGFR
Liu et al13 2018 NGS tissue Advanceda EGFR
Guibert et al25 2018 Tumor genotypingb and ddPCR in plasma Advanced EGFR
MET exon 14
Paweletz et al30 2016 Tissue genotype by FISH, PCR, or NGS Advanced EGFR
Wang et al28 2016 IHC and FISH Advanced ALK
Cui et al23 2017 IHC and FISH Advanceda ALK
Veldore et al27 2018 Real time PCR Metastatic EGFR
Leighl et al26 2019 Standard-of-care tissue testc Advanced EGFR
MET exon 14
Pritchett et al31 2019 NGS tissue Advanced EGFR
MET exon 14
Yao et al29 2017 NGS tissue Advanceda EGFR

Abbreviations: ALK, anaplastic lymphoma kinase; BRAF, serine/threonine-protein kinase B-Raf; EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; IHC, immunohistochemical; NGS, non-genetic sequencing; NTRK, neurotrophic receptor tyrosine kinase; MET, MET proto-oncogene, receptor tyrosine kinase; PCR, polymerase chain reaction; PD-L1, programmed death-ligand 1; RET, RET proto-oncogene; ROS-1, ROS proto-oncogene 1, receptor tyrosine kinase.

aThese studies also included patients in early stages but only data from advanced stage were considered.

bMethods of tissue genotyping were not described.

cNGS, PCR “hotspot” testing, FISH and/or IHC, or Sanger sequencing.

Quality of Eligible Studies

The methodologic quality of the studies was evaluated by QUADAS-2 and they are summarized in Table 2.

Table 2.Included Articles Quality Assessment According to QUADAS-2
Study Risk of Bias Applicability Concerns
Patient Selection Index Test Reference Standard Flow and Timing Patient Selection Index Test Reference Standard
Rachiglio et al24 LR ? ? LR LR ? ?
Liu et al13 LR ? ? LR LR LR LR
Guibert et al25 LR LR LR LR LR LR LR
Paweletz et al30 LR HR LR LR LR HR LR
Wang et al28 LR HR LR HR LR ? LR
Cui et al23 HR HR LR LR ? HR LR
Veldore et al27 LR LR LR ? LR LR LR
Leighl et al26 LR ? LR LR LR ? LR
Pritchett et al31 LR LR LR HR LR LR LR
Yao et al29 LR ? ? LR LR ? ?

Abbreviations: ?, unclear risk; HR, high risk; LR, low risk; QUADAS-2, Quality Assessment of Diagnostic Accuracy Tests.

Diagnostic Accuracy

The data extracted from each study regarding the six oncogenic driver mutations is described in Table 3. All the studies have demonstrated a specificity of 100%, except the Leighl et al26 that had one case of FP in MET exon 14. This alteration was not evaluated with other ctDNA methodologies as a reflex test. One of the studies, Rachilio et al,24 did show two FP results for EGFR mutations that were detected by NGS ctDNA, but considered EGFR wild type by tumor genotyping. Both EGFR mutations were confirmed by droplet digital PCR (ddPCR), so they were considered TP results. The sensitivity among the studies ranged from 54.5% to 92.1%. Figure 2 shows the plots of confidence regions of each study, describing the uncertainty of the pair of sensitivity and FP rate (1-specificity).

Table 3.Data Extracted from Each Study Included (EGFR, ALK, ROS-1, BRAF, RET, and MET exon 14)
Study TP FN FP TN Sensitivity (95% CI) Specificity (95% CI)
Rachiglio et al24 19 5 0 20 0.792 (0.578-0.929) 1.000 (0.832-1.000)
Liu et al13 13 7 0 84 0.650 (0.408-0.846) 1.000 (0.957-1.000)
Guibert et al25 41 3 0 76 0.932 (0.813-0.986) 1.000 (0.953-1.000)
Paweletz et al30 42 9 0 141 0.824 (0.691-0.916) 1.000 (0.974-1.000)
Wang et al28 19 5 0 36 0.792 (0.578-0.929) 1.000 (0.903-1.000)
Cui et al23 12 10 0 10 0.545 (0.322-0.756) 1.000 (0.692-1.000)
Veldore et al27 41 4 0 87 0.911 (0.788-0.975) 1.000 (0.958-1.000)
Leighl et al26 38 12 1 689 0.760 (0.618-0.869) 0.999 (0.992-1.000)
Pritchett et al31 23 13 0 711 0.639 (0.462-0.792) 1.000 (0.995-1.000)
Yao et al29 15 7 0 95 0.682 (0.451-0.861) 1.000 (0.962-1.000)

Abbreviations: ALK, anaplastic lymphoma kinase; BRAF, serine/threonine-protein kinase B-Raf; EGFR, epidermal growth factor receptor; FN, false negative; FP, false positive; MET, MET proto-oncogene, receptor tyrosine kinase; RET, RET proto-oncogene; TP, true positive; TN, true negative.

Figure 2
Figure 2.Confidence Interval of the Studies Included

The pooled sensitivity and specificity of NGS ctDNA were 0.766 (CI 95%: 0.678; 0.835) and 0.999 (95% CI: 0.990-1.000), respectively. The diagnostic accuracy, area under curve, reached 0.99.

The pooled DOR, which is the general diagnostic test performance, was 616.5 (95% CI: 263.0-1445.0). Heterogeneity investigation was performed among included studies, but they were considered homogeneous (Cochrane’s Q P = 0.437 and I2=0%).

As nine of 10 studies included in the analysis had a specificity of 100% and one study had a specificity of 99.9%, the sROC curve could not be generated.


The NCCN guideline recommends plasma testing to evaluate EGFR, ALK, ROS-1, BRAF, RET, and MET alterations when there is insufficient tissue material to guide the use of target therapies in patients with advanced or metastatic NSCLC.11 The results demonstrated that NGS ctDNA has a high accuracy to detect the six oncogenic driver mutations.

The meta-analysis demonstrated that NGS ctDNA reached an optimal specificity of 0.999 (95% CI: 0.990-1.000) which is a very important result to give confidence in prescribing target therapies in patients who will not be FPs for the six oncogenic driver mutations evaluated. The sensitivity reached an acceptable value of 0.766 (95% CI: 0.678-0.835).

These results support the recommendation by CAP/IASLC/AMP, which suggests that patients with positive results for EGFR, ALK, ROS-1, or BRAF with ctDNA NGS should start first-line therapy, as the results are considered reliable. However, a negative result from ctDNA NGS for oncogenic driver mutations cannot exclude therapies and further investigation is required.18 Therefore, the CAP/IASLC/AMP considers liquid biopsy not as a replacement for tissue biopsy but as an alternative when there is insufficient tumor tissue specimens or in cases where tissue specimens are not feasible.18 It is important to highlight that this recommendation was published before the FDA approval for MET exon 14 target therapy and RET fusion target therapy. With the MET exon 14 and RET fusion target therapies approvals in other countries, more guidelines may recommend the detection of these oncogenic driver mutations with tissue and plasma tests.

The comparator in systematic review was restricted to tissue genotyping in order to assess the sensitivity of the ctDNA NGS. However, the limitations of using tissue genotyping as the “gold standard” is the tumor heterogeneity which might be missed by tissue biopsies.32,33 Therefore, tumor heterogeneity can reduce overall concordance between plasma and tissue.34 Jiang et al. have shown that subjects with stage II–IV NSCLC showed more somatic mutations in plasma than tissue samples.34 One of the studies, Leighl et al,26 had a FP case in MET exon 14 that was detected by ctDNA NGS, but it was not detected by tissue genotyping. As this FP result was not evaluated with other ctDNA methodology as a reflex test, the MET exon 14 could be due to the heterogeneity of the tumor.

The present study demonstrated the feasibility of using ctDNA NGS in detecting six oncogenic driver mutations to help guide the target therapies in patients with aNSCLC. However, ctDNA NGS has also the potential to monitor patients’ response to therapies (target and immune therapies) and resistance mutations. Currently, the use of ctDNA is limited to cancer in advanced stages due to its low concentration in the early stages.


In conclusion, our meta-analysis supports the use of ctDNA NGS in clinical practice for those patients with advanced NSCLC who cannot undergo an invasive procedure or have insufficient tissue material for molecular tests. This technology provides a reliable alternative to guide the patients to the right treatment according to their molecular characteristics.


Conception and design: Rodrigo S. Ho, Mariana M. Sebastião

Collection and assembly of data: Rodrigo S. Ho, Mariana M. Sebastião

Data analysis and interpretation: All authors

Manuscript writing: Rodrigo S. Ho, Mariana M. Sebastião

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors


Mariana M. Sebastião

Employment: Roche Diagnostics Brazil

Rodrigo S. Ho

Employment: Roche Diagnostics Brazil

João Paulo V. de Carvalho

Employment: Roche Diagnostics LATAM

Micha Nussbaum

Employment: Roche Diagnostics Brazil

No other potential conflicts of interest were reported